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Background
Riociguat is the first of a new class of drugs, the soluble
guanylate cyclase (sGC) stimulators. Riociguat has a dual
mode of action: it sensitizes sGC to the body’so w nN O
and can also increase sGC activity in the absence of NO.
The NO-sGC-pathway is impaired in many cardiovascular
diseases such as heart failure, pulmonary hypertension and
diabetic nephropathy (DN). DN leads to high cardiovascu-
lar morbidity and mortality. There is still a high unmet
medical need. The urinary albumin excretion rate is a pre-
dictive biomarker for these clinical events. Therefore, we
investigated the effect of riociguat, alone and in combina-
tion with the angiotensin II receptor antagonist (ARB) tel-
misartan on the progression of DN in diabetic eNOS
knock out mice, a new model closely resembling human
pathology.
Methods
Seventy-six male eNOS knockout C57BL/6J mice were
divided into 4 groups after receiving intraperitoneal
high-dose streptozotocin: telmisartan (1 mg/kg), rioci-
guat (3 mg/kg), riociguat+telmisartan (3 and 1 mg/kg),
and vehicle. Fourteen mice were used as non-diabetic
controls. After 12 weeks, urine and blood were
obtained and blood pressure measured. Glucose con-
centrations were highly increased and similar in all
diabetic groups.
Results
Riociguat, alone (105.2 ± 2.5 mmHg; mean±SEM; n = 14)
and in combination with telmisartan (105.0 ± 3.2 mmHg;
n = 12), significantly reduced blood pressure versus dia-
betic controls (117.1 ± 2.2 mmHg; n = 14; p = 0.002
and p = 0.004, respectively), whereas telmisartan alone
(111.2 ± 2.6 mmHg) showed a modest blood pressure
lowering trend (p = 0.071; n = 14). The effects of single
treatment with either riociguat (97.1 ± 15.7 µg/d; n = 13)
or telmisartan (97.8 ± 26.4 µg/d; n = 14) did not signifi-
cantly lower albumin excretion on its own (p = 0.067 and
p = 0.101, respectively). However, the combined treat-
ment led to significantly lower urinary albumin excretion
(47.3 ± 9.6 µg/d; n = 12) compared to diabetic controls
(170.8 ± 34.2 µg/d; n = 13; p = 0.004), and reached levels
similar to non-diabetic controls (31.4 ± 10.1 µg/d,
n = 12).
Conclusion
Riociguat significantly reduced urinary albumin excretion
in diabetic eNOS knock out mice that were refractory to
treatment with ARB’s alone. Patients with diabetic
nephropathy refractory to treatment with ARB’sh a v et h e
worst prognosis among all patients with diabetic nephro-
pathy. Our data indicate that additional stimulation of
sGC on top of standard treatment with ARB`s may offer
a new therapeutic approach for patients with diabetic
nephropathy resistant to ARB treatment.
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